The Cardiovascular System: Structure, Function, and Regulation

Mohamad-Ali Salloum, PharmD • November 7, 2025

Share

  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button

A friendly, practical overview of how your heart and vessels work, what those BP numbers mean, and how common blood-pressure medicines help—using real-life examples you’ll recognize.

How Your Heart & Arteries Work (No Jargon)

Think of your body as a city. Your heart is the city’s pump station, and your blood vessels are the roads and pipes that deliver oxygen and nutrients to every “neighborhood” (your organs and muscles).

Everyday Example #1

Climbing stairs? Your “city” needs more oxygen. The pump speeds up and some roads widen so traffic (blood) flows faster where it’s needed—your leg muscles.

Everyday Example #2

Stand up too quickly and feel a head rush? Gravity pulls blood down briefly; sensors in your arteries nudge the pump to speed up and tighten a few roads so your brain keeps getting enough blood.

What Your BP Numbers Mean

Systolic (top number)

Pressure when the heart pushes. Picture the strong “drumbeat” that sends blood out to your body.

Diastolic (bottom number)

Pressure when the heart rests between beats. The quieter “pause” that still keeps blood gently moving.

The Sweet Spot

For most adults, around 120/80 mmHg is a healthy reading. Higher, long‑term numbers strain the “pipes” and the pump.

Blood Pressure Medicines—Explained Like a Friend

Most BP drugs help in one (or more) of four ways: less fluid in the system, a calmer pump, wider pipes, or quieter hormones/nerves. Here’s what that means in real life.

“Water Pills” (Diuretics)

Plain talk: Help your body pee out extra salt and water, so there’s less fluid for the pump to push.

Real-life example: After a salty meal, your rings feel tight? You’re holding water. Water pills help offload that extra fluid.

Heads‑up: You’ll pee more; sometimes potassium runs low. Your doctor may check your blood tests.

ACE Inhibitors & ARBs

Plain talk: Calm down a hormone system that tightens your vessels and makes you hold salt.

Real-life example: Like loosening a too‑tight faucet so water flows smoothly—less strain on the pipes.

Heads‑up: ACE inhibitors can cause a dry cough in some; ARBs usually don’t. Routine kidney and potassium checks are normal.

Calcium Channel Blockers

Plain talk: Relax the muscle in your vessel walls so the “roads” widen and traffic flows easier.

Real-life example: Opening more lanes on a highway—same traffic, less jam, lower pressure.

Heads‑up: Can cause ankle swelling or flushing; often taken once daily.

Beta‑Blockers

Plain talk: Tell the pump to take it easy—slower, steadier beats and lower force.

Real-life example: Like switching from sprinting to brisk walking—still moving blood, just gentler on the pump.

Heads‑up: Can cause tiredness or cooler hands/feet; great when there’s chest pain or certain rhythm issues.

Alpha‑Blockers

Plain talk: Loosen the “grip” on small arteries so they open a bit and pressure drops.

Real-life example: Helpful if you also have prostate symptoms (for people who do).

Heads‑up: First dose can make you light‑headed—bedtime dosing is common.

Central Calmers (e.g., Clonidine)

Plain talk: Quiet the nerve signals that tell vessels to clamp down.

Real-life example: Turning down a loudspeaker in a room; suddenly everyone relaxes.

Heads‑up: Missing doses can make BP bounce—tapering plans matter.

Direct Vasodilators

Plain talk: Directly open small arteries so resistance falls.

Real-life example: Like opening a side street to ease congestion on a busy road.

Heads‑up: Often paired with a beta‑blocker and a diuretic to balance side effects.

Three Real‑Life Stories

“Office Hours, Salty Snacks”

Layla works long hours and grabs chips at her desk. Her BP runs high in the afternoon. A small daily change—swapping salty snacks for nuts/fruit—and a once‑daily water pill helped her BP slide into the healthy zone within weeks.

“Runner with Family History”

Omar runs 3 times a week but both parents have hypertension. His home monitor shows borderline‑high readings. His doctor added a low‑dose ACE inhibitor. Result: steady 120s/70s and peace of mind for race day.

“Stubborn Numbers”

Rana takes three meds but clinic readings are still high. Her doctor checks home readings (to rule out “white‑coat” BP), reviews meds, and adds a low‑dose “water pill” that blocks a salt‑holding hormone. Within a month, her BP finally settles down.

Your BP Game Plan

  • Know your numbers: Check at a pharmacy or with a home cuff (seated, arm supported, feet on the floor, after 5 minutes of rest).
  • Salt sense: Taste your food before salting; look for “sodium” on labels—aim for fewer high‑sodium choices each week.
  • Move daily: 20–30 minutes of brisk walking most days beats a single long workout once a week.
  • Sleep & stress: Regular bedtime and simple breathing breaks keep the “pressure dial” calmer.
  • Meds matter: If you’re prescribed BP meds, take them as directed and don’t stop suddenly—ask about side effects and monitoring.

Friendly reminder: This guide is educational and not a substitute for personal medical advice. Always work with your healthcare professional for a plan that fits you.

Guidelines for Antihypertensive Therapy — Interactive Timeline

Explore landmark guideline updates across the US (JNC/ACC–AHA), Europe (ESC/ESH/ESH), and WHO.


Guidelines for Antihypertensive Therapy — Timeline

Scroll to explore. Click/tap the ℹ︎ on any card for thresholds & goals.

  1. 1977

    • US
    ℹ︎
    Treatment threshold : Persistent elevated office BP on repeat visits (numeric/out‑of‑office standards not yet formalized).
    Goal : Normalize BP using stepped‑care; goals were clinician‑directed rather than uniform numeric targets.
    Context: Early consensus; emphasis on detection & escalation.

    JNC 1: First national hypertension guideline

    Practical recommendations for detection, follow‑up, and stepped‑care drug therapy—set the template for later updates.

    Detection Stepped‑care Office BP
  2. 1993

    • US
    ℹ︎
    Treatment threshold : Typically ≥140/90 mmHg; treat isolated systolic hypertension in elderly.
    Goal : Generally <140/90 mmHg, with focus on systolic BP.
    Start with diuretic or β‑blocker unless compelling indications.

    JNC 5: Initial therapy emphasis

    Favored diuretics and β‑blockers as first‑line; refined classification and highlighted ABPM in select cases.

    Diuretics β‑blockers ABPM
  3. 2003/2004

    • US
    ℹ︎
    Treatment threshold : ≥140/90 (most); ≥130/80 for diabetes/CKD.
    Goal : <140/90 (most); <130/80 for diabetes/CKD.
    Introduced “pre‑hypertension” 120–139/80–89.

    JNC 7: ‘Pre‑hypertension’ and thiazides

    Created the pre‑HTN category and urged thiazide‑type diuretics as default initial drugs.

    Pre‑hypertension Thiazides Lifestyle
  4. 2014

    • US
    ℹ︎
    Treatment threshold : ≥150/90 (age ≥60); ≥140/90 (age <60), diabetes, or CKD.
    Goal : <150/90 (≥60); <140/90 (others).
    Initial: ACEi/ARB/CCB/thiazide.

    Panel Appointed to JNC 8 (JAMA)

    Outcome‑focused thresholds; simplified first‑line classes; NIH transitioned guideline stewardship.

    Targets First‑line
  5. 2017

    • US
    ℹ︎
    Categories : Normal <120/<80; Elevated 120–129/<80; Stage 1 130–139 or 80–89; Stage 2 ≥140 or ≥90.
    Treat : Stage 1 if 10‑yr ASCVD risk ≥10% or CVD/diabetes/CKD; Stage 2 → meds.
    Goal : <130/80 for most.

    ACC/AHA Comprehensive Guideline

    Redefined Stage 1 at 130/80; emphasized home/ambulatory confirmation.

    130/80 HBPM ABPM
  6. 2018

    • Europe
    ℹ︎
    Treat : Generally ≥140/90 (office) or out‑of‑office equivalents; earlier in high‑risk.
    Targets : First <140/90; then SBP 120–129 (<65 yrs) if tolerated; 130–139 (≥65 yrs); DBP <80.
    Prefer single‑pill combos.

    ESC/ESH Guideline

    European approach with individualized targets and single‑pill strategy.

    140/90 Single‑pill
  7. 2021

    • Global
    ℹ︎
    Treat : ≥140/90 (most); 130–139 SBP with CVD/high risk/diabetes/CKD.
    Targets : <140/90 (general); SBP <130 for established CVD if tolerated.
    Single‑pill combos; monthly follow‑up until control.

    WHO Pharmacological Guideline

    Pragmatic algorithms for primary care and population programs.

    WHO SPC
  8. 2023

    • Europe
    ℹ︎
    Treat : Typically ≥140/90 (office) or out‑of‑office equivalents; earlier in high risk.
    Targets : Step to <140/90, then SBP 120–129 if <65 and tolerated; 130–139 if ≥65; DBP <80.
    Resistant HTN pathway; prioritize single‑pill combos.

    ESH Guideline

    Strong emphasis on home/ambulatory BP and implementation.

    HBPM/ABPM Resistant HTN
  9. 2024

    • Europe
    ℹ︎
    Classification : Nonelevated <120/70; Elevated 120–139/70–89 (treat by risk & follow‑up); Hypertension ≥140/90.
    Default target : SBP 120–129 if tolerated (relax with intolerance/frailty/orthostasis).
    Streamlined diagnostic→treatment flow.

    ESC Guideline

    Simplified classification and care pathway for elevated BP & hypertension.

    Simplified Pathway

References:

  1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572. 
  2. American Heart Association (AHA) - "Types of Blood Pressure Medications" 
  3. Brunton L, Chabner B, Knollmann B. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th Edition. McGraw Hill Professional; 2010. 
  4. National Heart, Lung, and Blood Institute (NHLBI) - "How High Blood Pressure Medications Work" 
  5. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. 
  6. Mayo Clinic - "Antihypertensive Drugs" 



List of Services

    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button

    ABOUT THE AUTHOR

    Mohamad-Ali Salloum, PharmD

    Mohamad Ali Salloum LinkedIn Profile

    Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.

    Share

    Recent articles:

    By Mohamad-Ali Salloum, PharmD May 23, 2026
    Why does this always happen?
    By Mohamad-Ali Salloum, PharmD May 21, 2026
    Discover the best ways to learn new skills
    By Mohamad-Ali Salloum, PharmD May 19, 2026
    Stuck in your head? Discover why overthinking feels productive, how it sabotages your performance, and simple ways to shift into real action.
    By Mohamad-Ali Salloum, PharmD May 17, 2026
    References: Wood W, Quinn JM, Kashy DA. Habits in everyday life: Thought, emotion, and action. J Pers Soc Psychol . 2002;83(6):1281–1297. Wood W, Neal DT. The habitual consumer. J Consum Psychol . 2009;19(4):579–592. Neal DT, Wood W, Labrecque JS, Lally P. How do habits guide behavior? Perceived and actual triggers of habits in daily life. J Exp Soc Psychol . 2012;48(2):492–498. Wood W, Mazar A, Neal DT. Habits and goals in human behavior: Separate but interacting systems. Perspect Psychol Sci . 2021;16(1):1–16. Graybiel AM. Habits, rituals, and the evaluative brain. Annu Rev Neurosci . 2008;31:359–387. Smith KS, Graybiel AM. Habit formation. Dialogues Clin Neurosci . 2016;18(1):33–43. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci . 2006;7(6):464–476. Graybiel AM. The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem . 1998;70(1–2):119–136. Schultz W. Dopamine reward prediction error coding. Dialogues Clin Neurosci . 2016;18(1):23–32. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science . 1997;275(5306):1593–1599. Nasser HM, Calu DJ, Schoenbaum G, Sharpe MJ. The dopamine prediction error: Contributions to associative models of reward learning. Front Psychol . 2017;8:244. Kahnt T, Schoenbaum G. The curious case of dopaminergic prediction errors and learning associative information beyond value. Nat Rev Neurosci . 2025;26:169–178. Lally P, van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: Modelling habit formation in the real world. Eur J Soc Psychol . 2010;40(6):998–1009. American Psychological Association. Harnessing the power of habits. Monitor Psychol . 2020;51(8):78–83.
    By Mohamad-Ali Salloum, PharmD May 15, 2026
    References: Baddeley A. Working memory: theories, models, and controversies. Annu Rev Psychol . 2012;63:1–29. Chai WJ, Abd Hamid AI, Malin Abdullah J. Working memory from the psychological and neurosciences perspectives: a review. Front Psychol . 2018;9:401. Rogers RD, Monsell S. Costs of a predictable switch between simple cognitive tasks. J Exp Psychol Gen . 1995;124(2):207–231. Rubinstein JS, Meyer DE, Evans JE. Executive control of cognitive processes in task switching. J Exp Psychol Hum Percept Perform . 2001;27(4):763–797. Garner KG, Dux PE. Knowledge generalization and the costs of multitasking. Nat Rev Neurosci . 2023;24:98–112. Zhou X, Lei X. Wandering minds with wandering brain networks. Neurosci Bull . 2018;34(6):1017–1028. Sorella S, Crescentini C, Matiz A, et al. Resting‑state default mode network variability predicts spontaneous mind‑wandering. Front Hum Neurosci . 2025;19:1515902. Sweller J. Cognitive load during problem solving: effects on learning. Cogn Sci . 1988;12(2):257–285. 
    By Mohamad-Ali Salloum, PharmD May 13, 2026
    Why do we procrastinate even when tasks matter most? Discover the emotional roots of procrastination and how to stop
    By Mohamad-Ali Salloum, PharmD May 11, 2026
    Confidence and self-esteem are often confused but are psychologically distinct. Learn how they differ, how each develops, and why understanding both matters for real growth.
    By Mohamad-Ali Salloum, PharmD May 9, 2026
    Confidence isn’t about eliminating fear—it’s about acting despite it. Discover how courage, discomfort, and psychological growth build real confidence over time.
    By Mohamad-Ali Salloum, PharmD May 7, 2026
    References: McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014;371(11):993–1004. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007;357:2109–2122. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med . 2008;358:1431–1443. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545–2559. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med . 1991;324:781–788. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on cardiovascular and renal outcomes. N Engl J Med . 2020;383:1413–1424. Ioannidis JPA. Surrogate endpoints in clinical trials: are we being misled? BMJ . 2013;346:f314.
    By Mohamad-Ali Salloum, PharmD May 4, 2026
    References: Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci . 2015;16(7):403‑18. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects associated with pharmacological interventions: an umbrella review. BMJ Open . 2023;13:e077243. Colloca L, Finniss D. Nocebo effects, patient‑clinician communication, and therapeutic outcomes. JAMA . 2012;307(6):567‑8. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a blinded, randomized trial of statin, placebo, and no treatment. N Engl J Med . 2021;385(23):2180‑9. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the “drucebo” effect in statin therapy. J Cachexia Sarcopenia Muscle . 2018;9(6):1023‑33. Barnes K, Faasse K, Geers AL, et al. Can positive framing reduce nocebo side effects? Front Pharmacol . 2019;10:167. Caliskan EB, Bingel U, Kunkel A. Translating knowledge on placebo and nocebo effects into clinical practice. Pain Rep . 2024;9(2):e1142. von Wernsdorff M, Loef M, Tuschen‑Caffier B, Schmidt S. Effects of open‑label placebos in clinical trials: a systematic review and meta‑analysis. Sci Rep . 2021;11:3855.
    More Posts